Skip to main content
SpringerLink
Log in

Medication-Induced Neurotoxicity in Critically Ill Cancer Patients

  • Reference work entry
  • First Online:
Oncologic Critical Care

Abstract

Neurotoxicity associated with cancer treatment and treatment for medical and surgical complications of cancer have been well recognized. Elderly patients, advanced cancer, concomitant polypharmacy, organ failure, and medical comorbidities are all confounders contributing to adverse events related to cancer therapy. Short-term and long-term neurotoxicities may lead to disabilities and poor quality of life in patients with cancer. As a result of early detection of cancer and advances in treatment, cancer survival rates have improved consistently over the last decades and thus long-term survivors may face physical and psychological challenges associated with cancer and cancer treatment. As such, understanding the pathogenic mechanisms, optimizing the strategies for clinical assessment and interventions for the management and prevention of medication-related neurotoxicity is of paramount importance in patient care.

This chapter will address the neurotoxicity induced by a number of drug classes commonly used in the treatment of cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29:93–100.

    Article  CAS  PubMed  Google Scholar 

  2. Robertson GL, Bhoopalam N, Zelkowitz LI. Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med. 1973;132:717–20.

    Article  CAS  PubMed  Google Scholar 

  3. Whittaker JA, Parry DH, Bunch C, Weatherall DJ. Coma associated with vincristine therapy. Br Med J. 1973;4:335–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Boranic M, Raci F. A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. Biomedicine. 1979;31:124–5.

    CAS  PubMed  Google Scholar 

  5. Byrd RL, Rohrbaugh TM, Raney RB Jr, Norris DG. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer. 1981;47:37–40.

    Article  CAS  PubMed  Google Scholar 

  6. Dallera F, Gamoletti R, Costa P. Unilateral seizures following vincristine intravenous injection. Tumori. 1984;70:243–4.

    Article  CAS  PubMed  Google Scholar 

  7. Scheithauer W, Ludwig H, Maida E. Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Investig New Drugs. 1985;3:315–8.

    Article  CAS  Google Scholar 

  8. Hurwitz RL, Mahoney DH, Armstrong DL, Browder TM. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol. 1988;16:216–9.

    Article  CAS  PubMed  Google Scholar 

  9. Gaidys WG, Dickerman JD, Walters CL, Young PC. Report of a fatal case despite CNS washout. Cancer. 1983;52:799–801.

    Article  CAS  PubMed  Google Scholar 

  10. Walther PJ, Rossitch E, Bullard DE. The development of Lhermitte’s sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination. Cancer. 1987;60:2170–2.

    Article  CAS  PubMed  Google Scholar 

  11. DeAngelis LM, Posner JB. Neurologic complications of cancer. 2nd ed. Oxford: Oxford University Press; 2009.

    Google Scholar 

  12. Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R. Docetaxel-induced nail changes – a neurogenic mechanism: a case report. J Neuro-Oncol. 2002;58:167–74.

    Article  Google Scholar 

  13. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2001:CD005228. https://doi.org/10.1002/14651858.CD005228.pub3; 1–48

  14. Chabner B, Longo DL. Cancer chemotherapy and biotherapy: principles and practice. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.

    Google Scholar 

  15. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med. 2009;219:177–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Icli F, Karaoguz H, Dincol D, Demirkazik A, Gunel N, Karaoguz R, Oner A. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72:587–93.

    Article  CAS  PubMed  Google Scholar 

  17. Lyass O, Lossos A, Hubert A, Gips M, Peretz T. Cisplatin-induced non-convulsive encephalopathy. Anti-Cancer Drugs. 1998;9:100–4.

    Article  CAS  PubMed  Google Scholar 

  18. Renard D, Westhovens R, Vandenbussche E, Vandenberghe R. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol. 2004;251:226–8.

    Article  PubMed  Google Scholar 

  19. Kiewe P, Seyfert S, Korper S, Rieger K, Thiel E, Knauf W. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma. 2003;44:1815–8.

    Article  PubMed  Google Scholar 

  20. Benger A, Browman GP, Walker IR, Preisler HD. Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemiaintergroup report. Cancer Treat Rep. 1985;6:240–1.

    Google Scholar 

  21. Scherokman B, Filling-Katz MR, Tell D. Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia. Cancer Treat Rep. 1985;69:1005–6.

    CAS  PubMed  Google Scholar 

  22. Borgeat A, De Muralt B, Stalder M. Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer. 1986;58:852–4.

    Article  CAS  PubMed  Google Scholar 

  23. Nagarajan R, Peters C, Orchard P, Rydholm N. Report of severe neurotoxicity with cyclophosphamide. J Pediatr Hematol Oncol. 2000;22:544–6.

    Article  CAS  PubMed  Google Scholar 

  24. Kende G, Sirkin SR, Thomas PR, Freeman AI. Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer. 1979;44:69–71.

    Article  CAS  PubMed  Google Scholar 

  25. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11:6767–71.

    Article  CAS  PubMed  Google Scholar 

  26. Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, Lachance DH, Liu H, Shelerud RA, Cheville AL, Loprinzi CL. Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2015;23:943–51.

    Article  PubMed  Google Scholar 

  27. Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol. 2017; https://doi.org/10.2174/1570159X15666170915143217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Park SB, Goldstein D, Krishman AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. Cancer J Clin. 2013;63:419–37.

    Article  Google Scholar 

  29. Quigley C, Joel S, Patel N, Baksh A, Slevin M. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med. 2003;17:185–90.

    Article  PubMed  Google Scholar 

  30. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs. 2001;61:955–77.

    Article  CAS  PubMed  Google Scholar 

  31. Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manag. 1994;9:372–82.

    Article  CAS  Google Scholar 

  32. Oosten AW, Oldenmenger WH, Mathijssen RH, van der Rijt CC. A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain. 2015;16:935–46.

    Article  PubMed  Google Scholar 

  33. De Conno F, Ripamonti C, Fagnoni E, Brunelli C, Luzzani M, Maltoni M, Arcuri E, Bertetto O. The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during ‘titration phase’ in patients with cancer pain. Palliat Med. 2008;22:214–21.

    Article  CAS  PubMed  Google Scholar 

  34. Mercadante S, Casuccio A, Agnello A, Serreta R, Calderone L, Baressi L. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol. 1998;16:3656–61.

    Article  CAS  PubMed  Google Scholar 

  35. Lawlor PG. The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer. 2002;94:1836–53.

    Article  CAS  PubMed  Google Scholar 

  36. Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manag. 1997;14:51–8.

    Article  CAS  Google Scholar 

  37. Folstein MF, Fetting JH, Lobo A, Naiz U, Capozzoli KD. Cognitive assessment of cancer patients. Cancer. 1984;53:2250–7.

    Article  CAS  PubMed  Google Scholar 

  38. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend. 2001;63:139–46.

    Article  CAS  PubMed  Google Scholar 

  39. Lotsch J. Opioid metabolites. J Pain Symptom Manag. 2005;29:S10–24.

    Article  CAS  Google Scholar 

  40. Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Rogers AG, Inturissi CE, Reidenberg MM. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol. 1983;13:180–5.

    Article  CAS  PubMed  Google Scholar 

  41. Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am. 2002;16:543–55.

    Article  PubMed  Google Scholar 

  42. Morita T, Tei Y, Tsunoda J, Inoue S, Chihara S. Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manag. 2001;22:997–1006.

    Article  CAS  Google Scholar 

  43. Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manag. 2004;27:268–73.

    Article  Google Scholar 

  44. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain. 1998;74:5–9.

    Article  CAS  PubMed  Google Scholar 

  45. Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res. 2001;86:56–62.

    Article  CAS  PubMed  Google Scholar 

  46. Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12:679–84.

    PubMed  Google Scholar 

  47. Ross JR, Riley J, Quigley C, Welsh KI. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006;11:765–73.

    Article  CAS  PubMed  Google Scholar 

  48. Cherny NI. The management of cancer pain. CA Cancer J Clin. 2000;50:70–116, quiz 117–20.

    Article  CAS  PubMed  Google Scholar 

  49. Bromfield EB. Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis. 2004;1(Suppl 1):S27–33.

    PubMed  Google Scholar 

  50. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313:145–51.

    Article  CAS  PubMed  Google Scholar 

  51. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159–68.

    Article  PubMed  Google Scholar 

  52. Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR Jr, Hirsch LJ. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009;14:202–9.

    Article  PubMed  Google Scholar 

  53. Karas BJ, Wilder BJ, Hammond EJ, Bauman AW. Valproate tremors. Neurology. 1982;32:428–32.

    Article  CAS  PubMed  Google Scholar 

  54. Jamora D, Lim SH, Pan A, Tan L, Tan EK. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007;22:130–3.

    Article  PubMed  Google Scholar 

  55. Kokenge R, Kutt H, McDowell F. Neurological sequelae following Dilantin overdose in a patient and in experimental animals. Neurology. 1965;15:823–9.

    Article  CAS  PubMed  Google Scholar 

  56. Munoz-Garcia D, Del Ser T, Bermejo F, Portera A. Truncal ataxia in chronic anticonvulsant treatment. Association with drug-induced folate deficiency. J Neurol Sci. 1982;55:305–11.

    Article  CAS  PubMed  Google Scholar 

  57. De Marcos FA, Ghizoni E, Kobayashi E, Li LM, Cendes F. Cerebellar volume and long-term use of phenytoin. Seizure. 2003;12:312–5.

    Article  PubMed  Google Scholar 

  58. Hamed SA, Abdellah MM. The relationship between valproate induced tremors and circulating neurotransmitters: a preliminary study. Int J Neurosci. 2017;127:236–42.

    Article  CAS  PubMed  Google Scholar 

  59. Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, Paul RG. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology. 1996;47:626–35.

    Article  CAS  PubMed  Google Scholar 

  60. Meador KJ, Loring DW, Moore EE, Thompson WO, Nichols ME, Oberzan RE, Durkin MW, Gallagher BB, King DW. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology. 1995;45:1494–9.

    Article  CAS  PubMed  Google Scholar 

  61. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(Suppl 2):S18–22.

    Article  CAS  PubMed  Google Scholar 

  62. Alonso-Juarez M, Torres-Russotto D, Crespo-Morfin P, Baizabal-Carvallo JF. The clinical features and functional impact of valproate-induced tremor. Parkinsonism Relat Disord. 2017;44:147–50.

    Article  PubMed  Google Scholar 

  63. Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, Schuetz EG, Evans WE. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet. 2000;356:285–90.

    Article  CAS  PubMed  Google Scholar 

  64. Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neuro-Oncol. 2012;108:499–506.

    Article  CAS  Google Scholar 

  65. Avila EK, Graber J. Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep. 2010;10:60–7.

    Article  PubMed  Google Scholar 

  66. Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol. 2001;22:1901–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA. FK506-induced neurotoxicity in liver transplantation. Ann Neurol. 1994;35:498–501.

    Article  CAS  PubMed  Google Scholar 

  68. Masetti R, Cordelli DM, Zama D, Vendemini F, Baigi C, Franzoni E, Pession A. PRES in children undergoing hematopoietic stem cell or solid organ transplantation. Pediatrics. 2015;135:890–901.

    Article  PubMed  Google Scholar 

  69. Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl. 2001;7:937–42.

    Article  CAS  PubMed  Google Scholar 

  70. Ayres RC, Dousset B, Wixon S, Buckels JA, McMaster P, Mayer AD. Peripheral neurotoxicity with tacrolimus. Lancet. 1994;343:862–3.

    Article  CAS  PubMed  Google Scholar 

  71. Chohan R, Vij R, Adkins D, Blum W, Brown R, Tomasson M, Devine S, Graubert T, Goodnough LT, Dipersio JF, Khoury H. Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. Br J Haematol. 2003;123:110–3.

    Article  PubMed  Google Scholar 

  72. Nishiguchi T, Mochizuki K, Shakudo M, Takeshita T, Hino M, Inoue Y. CNS complications of hematopoietic stem cell transplantation. AJR Am J Roentgenol. 2009;192:1003–11.

    Article  PubMed  Google Scholar 

  73. Marra A, Vargas M, Striano P, Del Guercio L, Buonanno P, Servillo G. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses. 2014;82:619–22.

    Article  CAS  PubMed  Google Scholar 

  74. Baumgartel K, Mansuy IM. Neural functions of calcineurin in synaptic plasticity and memory. Learn Mem. 2012;19:375–84.

    Article  CAS  PubMed  Google Scholar 

  75. Wijdicks EF, Dahlke LJ, Wiesner RH. Oral cyclosporine decreases severity of neurotoxicity in liver transplant recipients. Neurology. 1999;52:1708–10.

    Article  CAS  PubMed  Google Scholar 

  76. Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med. 2001;345:425–32.

    Article  CAS  PubMed  Google Scholar 

  77. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neuro-Oncol. 2016;128:75–84.

    Article  Google Scholar 

  79. Lamy C, Oppenheim C, Meder JF, Mas JF. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging. 2014;14:89–96.

    Article  Google Scholar 

  80. Pinedo DM, Shah-Khan F, Shah PC. Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. J Clin Oncol. 2007;25:5320–1.

    Article  PubMed  Google Scholar 

  81. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Epilepsy based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48–61.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Monica E. Loghin & Anne Kleiman

Authors
  1. Monica E. Loghin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Kleiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monica E. Loghin .

Editor information

Editors and Affiliations

  1. Department of Critical Care and Respiratory Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Joseph L. Nates

  2. Division of Anesthesiology, Critical Care and Pain Medicine, Department of Critical Care and Respiratory Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Kristen J. Price

Section Editor information

  1. Critical Care Department, Universidad del Rosario Hospital Universitario Fundacion Santa Fe de, Bogota, Colombia, Colombia

    Yenny Cardenas

Rights and permissions

Reprints and permissions

Copyright information

© 2020 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Loghin, M.E., Kleiman, A. (2020). Medication-Induced Neurotoxicity in Critically Ill Cancer Patients. In: Nates, J., Price, K. (eds) Oncologic Critical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-74588-6_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74588-6_32

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74587-9

  • Online ISBN: 978-3-319-74588-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation